Total buying$00 buys
ORIC
Oric Pharmaceuticals, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$275k5 sells
Net open-market−$275kBuying minus selling
Active insiders2Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 02, 2026
Open-market transaction mix · 5 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 3 | 0 | $0 | $189k | -$189k |
| Oct 2026 | 0 | 2 | 0 | $0 | $86.5k | -$86.5k |
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (1)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- PD-$128.3k
- HA-$80.9k
ORIC transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
ORICOric Pharmaceuticals, Inc. | Heyman Richard A.DIR | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ORICOric Pharmaceuticals, Inc. | Heyman Richard A.DIR | S · sale10b5-1 detectedSEC filing ↗ | -$41.3kView disclosure → | |
ORICOric Pharmaceuticals, Inc. | Heyman Richard A.DIR | S · sale10b5-1 detectedSEC filing ↗ | -$45.1kView disclosure → | |
ORICOric Pharmaceuticals, Inc. | Heyman Richard A.DIR | M · exercise10b5-1 detectedSEC filing ↗ | $5.60kView disclosure → | |
ORICOric Pharmaceuticals, Inc. | Piscitelli DominicCFO | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ORICOric Pharmaceuticals, Inc. | Piscitelli DominicCFO | S · sale10b5-1 detectedSEC filing ↗ | -$181kView disclosure → | |
ORICOric Pharmaceuticals, Inc. | Piscitelli DominicCFO | M · exercise10b5-1 detectedSEC filing ↗ | $58.4kView disclosure → | |
ORICOric Pharmaceuticals, Inc. | Piscitelli DominicCFO | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ORICOric Pharmaceuticals, Inc. | Piscitelli DominicCFO | S · sale10b5-1 detectedSEC filing ↗ | -$6.75kView disclosure → | |
ORICOric Pharmaceuticals, Inc. | Piscitelli DominicCFO | S · sale10b5-1 detectedSEC filing ↗ | -$1.35kView disclosure → | |
ORICOric Pharmaceuticals, Inc. | Piscitelli DominicCFO | M · exercise10b5-1 detectedSEC filing ↗ | $2.61kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period11transactionstxns
- M · Option exercise · dominant6 · 55%
- S · Open-market sells5 · 45%
Activity by reported role
A joint filing can contribute to multiple rolesChief financial officer7
Director4
Reported Holdings After
Separated by insider, security, and ownership type
Piscitelli DominicCommon Stock · Direct
69,828Sep 28, 2026
Piscitelli DominicStock Option (right to buy) · Direct
78,500Sep 28, 2026
Heyman Richard A.Common Stock · Direct
38,300Oct 01, 2026
Heyman Richard A.Common Stock · Indirect · See footnote
203,472Oct 01, 2026
Heyman Richard A.Stock Option (right to buy) · Direct
26,700Oct 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Oric Pharmaceuticals, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Oric Pharmaceuticals, Inc.?
Heyman Richard A., Piscitelli Dominic.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Heyman Richard A. reported a sale on Oct 01, 2026 valued at $41.3k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $275,884.75. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.